dihydroconiferyl alcohol: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
dihydroconiferyl alcohol : A member of class of phenols that is 2-methoxyphenol substituted by a 3-hydroxypropyl group at position 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 16822 |
| CHEMBL ID | 4207816 |
| CHEBI ID | 4559 |
| SCHEMBL ID | 200345 |
| MeSH ID | M0278210 |
| Synonym |
|---|
| nsc-4591 |
| nsc4591 |
| 1-propanol, 3-(4-hydroxy-3-methoxyphenyl)- |
| benzenepropanol, 4-hydroxy-3-methoxy- |
| 1-propanol, 3-(4-hydroxy-3-methoxyphenyl) |
| 4-hydroxy-3-methoxy-benzenepropanol |
| 2305-13-7 |
| dihydroconiferyl alcohol |
| BMSE000585 |
| 4-(3-hydroxypropyl)-2-methoxyphenol |
| BMSE010186 |
| dihydro-coniferyl alcohol |
| FT-0695039 |
| 3-(4-hydroxy-3-methoxyphenyl)-1-propanol |
| nsc 4591 |
| l6399t797s , |
| unii-l6399t797s |
| dihydroconiferylalcohol |
| AKOS005217790 |
| BRD-K43807558-001-01-6 |
| 3-(3-methoxy-4-hydroxyphenyl)propyl alcohol |
| SCHEMBL200345 |
| 4-(3-hydroxypropyl)-2-methoxy-phenol |
| 3-(4-guaiacyl)propanol |
| guaiacyl propanol |
| 3-(4-hydroxy-3-methoxyphenyl)-propan-1-ol |
| CHEBI:4559 , |
| DTXSID70177612 |
| benzenepropanol, 4-hydroxy-3-methoxy- (9ci) |
| mfcd00016571 |
| CS-W017109 |
| F17046 |
| EN300-1866116 |
| Q27106409 |
| 3-(3-methoxy-4-hydroxyphenyl)-1-propanol |
| guaiacyl-3-propanol |
| coniferyl alcohol, dihydro- |
| 1-guaiacyl-3-propanol |
| A878345 |
| 3-(4-hydroxy-3-methoxyphenyl)-1-propanol;dihydroconiferyl alcohol |
| CHEMBL4207816 |
| 4-hydroxy-3-methoxybenzenepropanol |
| HY-W016393 |
| SY057894 |
| Role | Description |
|---|---|
| plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| primary alcohol | A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it. |
| eugenol | A phenylpropanoid formally derived from guaiacol with an allyl chain substituted para to the hydroxy group. It is a major component of clove essential oil, and exhibits antibacterial, analgesic and antioxidant properties. It has been widely used in dentistry to treat toothache and pulpitis. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| monolignol glucosides biosynthesis | 1 | 11 |
| dihydroconiferyl alcohol biosynthesis | 0 | 6 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1378424 | Activation of HSF1 in human NCI-H460 cells expressing pGL4-hsp25 construct assessed as upregulation of hsp25 promoter activity at 10 to 30 uM after 12 hrs by luciferase reporter gene assay | 2017 | Journal of natural products, 08-25, Volume: 80, Issue:8 | The Conjugated Double Bond of Coniferyl Aldehyde Is Essential for Heat Shock Factor 1 Mediated Cytotoprotection. |
| AID1378426 | Activation of HSF1 in human NCI-H460 cells expressing pGL4-hsp70 construct assessed as upregulation of hsp70 promoter activity at 10 to 30 uM after 12 hrs by luciferase reporter gene assay | 2017 | Journal of natural products, 08-25, Volume: 80, Issue:8 | The Conjugated Double Bond of Coniferyl Aldehyde Is Essential for Heat Shock Factor 1 Mediated Cytotoprotection. |
| AID1378428 | Activation of HSF1 in human NCI-H460 cells assessed as upregulation of HSP25 protein levels at 10 to 30 uM after 12 hrs by Western blot analysis | 2017 | Journal of natural products, 08-25, Volume: 80, Issue:8 | The Conjugated Double Bond of Coniferyl Aldehyde Is Essential for Heat Shock Factor 1 Mediated Cytotoprotection. |
| AID1378427 | Upregulation of HSF1 protein level in human NCI-H460 cells at 10 to 30 uM after 12 hrs by Western blot analysis | 2017 | Journal of natural products, 08-25, Volume: 80, Issue:8 | The Conjugated Double Bond of Coniferyl Aldehyde Is Essential for Heat Shock Factor 1 Mediated Cytotoprotection. |
| AID1378429 | Activation of HSF1 in human NCI-H460 cells assessed as upregulation of HSP70 protein levels at 10 to 30 uM after 12 hrs by Western blot analysis | 2017 | Journal of natural products, 08-25, Volume: 80, Issue:8 | The Conjugated Double Bond of Coniferyl Aldehyde Is Essential for Heat Shock Factor 1 Mediated Cytotoprotection. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.11) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (87.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||